The unique alterations of hippocampus and cognitive impairment in chronic obstructive pulmonary disease

Respiratory Research

Volumn 14, Issue 1, 2013, Pages

  Li, Jing ^a   Fei, Guang He ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Cognitive impairment; Hippocampus; Pulmonary function; S100B

Indexed keywords

AMBROXOL; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; PROTEIN S100B; SALBUTAMOL; BIOLOGICAL MARKER; S100B PROTEIN, HUMAN;

AGED; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; ARTICLE; BODY MASS; BRAIN ATROPHY; BRAIN SIZE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EDUCATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIPPOCAMPUS; HUMAN; HYPOXEMIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; OXYGEN SATURATION; OXYGEN THERAPY; SMOKING; ATROPHY; BLOOD; BLOOD GAS ANALYSIS; CASE CONTROL STUDY; INCIDENCE; LUNG FUNCTION TEST; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ATROPHY; BIOLOGICAL MARKERS; BLOOD GAS ANALYSIS; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; HIPPOCAMPUS; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SEVERITY OF ILLNESS INDEX;

EID: 84903854709     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-140     Document Type: Article

References (33)

1. Grant I, Heaton RK, McSweeny AJ, Adams KM, Timms RM: Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med. 1982, 142: 1470-1476. 10.1001/archinte.1982.00340210062015.
2. van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration. 2008, 75: 224-238. 10.1159/000111820.
3. Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009, 33: 1165-1185. 10.1183/09031936.00128008.
4. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010, 80: 112-119. 10.1159/000281880.
5. Antonelli Incalzi R, Marra C, Giordano A, Calcagni ML, Cappa A, Basso S, Pagliari G, Fuso L: Cognitive impairment in chronic obstructive pulmonary disease-a neuropsychological and spect study. J Neurol. 2003, 250: 325-332. 10.1007/s00415-003-1005-4.
6. Kirkil G, Tug T, Ozel E, Bulut S, Tekatas A, Muz MH: The evaluation of cognitive functions with P300 test for chronic obstructive pulmonary disease patients in attack and stable period. Clin Neurol Neurosurg. 2007, 109: 553-560. 10.1016/j.clineuro.2007.03.013.
7. Hung WW, Wisnivesky JP, Siu AL, Ross JS: Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009, 180: 134-137. 10.1164/rccm.200902-0276OC.
8. Dodd JW, Getov SV, Jones PW: Cognitive function in COPD. Eur Respir J. 2010, 35: 913-922. 10.1183/09031936.00125109.
9. Li J, Huang Y, Fei GH: The evaluation of cognitive impairment and relevant factors in patients with chronic obstructive pulmonary disease. Respiration. 2013, 85: 98-105. 10.1159/000342970.
10. Dawe RJ, Bennett DA, Schneider JA, Arfanakis K: Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. PLoS One. 2011, 6: e26286-10.1371/journal.pone.0026286.
11. Zhang J, Yu C, Jiang G, Liu W, Tong L: 3D texture analysis on MRI images of Alzheimer's disease. Brain Imaging Behav. 2012, 6: 61-69. 10.1007/s11682-011-9142-3.
12. Apostolova LG, Green AE, Babakchanian S, Hwang KS, Chou YY, Toga AW, Thompson PM: Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord. 2012, 26: 17-27. 10.1097/WAD.0b013e3182163b62.
13. Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, Woo E, Cummings JL, Toga AW, Jack CR, Weiner MW, Thompson PM: Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage. 2010, 51: 488-499. 10.1016/j.neuroimage.2009.12.125.
14. Sen J, Belli A: S100B in neuropathologic states: the CRP of the brain?. J Neurosci Res. 2007, 85: 1373-1380. 10.1002/jnr.21211.
15. Winocur G, Roder J, Lobaugh N: Learning and memory in S100-beta transgenic mice: an analysis of impaired and preserved function. Neurobiol Learn Mem. 2001, 75: 230-243. 10.1006/nlme.2000.3961.
16. Sheng JG, Mrak RE, Griffin WS: S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res. 1994, 39: 398-404. 10.1002/jnr.490390406.
17. Van Eldik LJ, Griffin WS: S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim Biophys Acta. 1994, 1223: 98-403.
18. Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS: S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem. 1998, 71: 1421-1428.
19. Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, Kipp F, Abel S, Siegmund A, Suslow T, von Eiff C, Arolt V, Rothermundt M: Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 3: 1789-1792.
20. Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall'Igna O, Mazzini GS, Souza DO, Portela LV: Serum levels of S100B and NSE proteins in Alzheimer's disease patients. J Neuroinflammation. 2010, 7: 6. Doi: 10.1186/1742-2094-7-6.
21. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 guidelines. http://www.csrd.org.cn/ppt/upload/201268164.pdf.
22. Watson C, Andermann F, Gloor P, Jones-Gotman M, Peters T, Evans A, Olivier A, Melanson D, Leroux G: Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology. 1992, 42: 1743-1750. 10.1212/WNL.42.9.1743.
23. Bartko JJ, Carpenter WT: On the methods and theory of reliability. J Nerv Ment Dis. 1976, 163: 307-317. 10.1097/00005053-197611000-00003.
24. Jack CR, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD: Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology. 1989, 172: 549-554.
25. Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D: Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage. 2005, 25: 783-792. 10.1016/j.neuroimage.2004.12.036.
26. Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ: Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol. 2007, 42: 129-138. 10.1016/j.exger.2006.05.016.
27. Arlt S, Buchert R, Spies L, Eichenlaub M, Lehmbeck JT, Jahn H: Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2013, 263: 335-344. 10.1007/s00406-012-0350-7.
28. Daulatzai MA: Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. J Alzheimers Dis. 2010, 20: 355-367.
29. Daulatzai MA: Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease. Neurochem Res. 2012, 37: 2627-2658. 10.1007/s11064-012-0854-6.
30. Canessa N, Castronovo V, Cappa SF, Aloia MS, Marelli S, Falini A, Alemanno F, Ferini-Strambi L: Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. Am J Respir Crit Care Med. 2011, 183: 1419-1426. 10.1164/rccm.201005-0693OC.
31. Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C: The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 1999, 52: 1158-1165. 10.1212/WNL.52.6.1158.
32. Van Eldik LJ, Wainwright MS: The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci. 2003, 21: 97-108.
33. Braga CW, Martinez D, Wofchuk S, Portela LV, Souza DO: S100B and NSE serum levels in obstructive sleep apnea syndrome. Sleep Med. 2006, 7: 431-435. 10.1016/j.sleep.2005.12.012.